American College of Clinical Pharmacology

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

Retrieved on: 
Wednesday, August 30, 2023
Biotechnology, Health, Clinical Trials, ACCP, American College of Clinical Pharmacology, Development of the human body, DSM-IV codes, Medication, Plasma, Pharmacokinetics, Annual general meeting, IEC, Prolactin, Seizure, American College, QEEG, Pharmaceutical industry, Safety, Pharmacology

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.
  • Title: The PACIFIC Study: A Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758)
    Title: Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist (#754)
    Title: Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist (#749)
    Title: A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics, and QEEG Changes Reflecting Receptor Engagement (#060)

Alector Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 3, 2023
Amyloid-related imaging abnormalities, ACCP, Alector, European Medicines Agency, GPNMB, Interest, Plasma, AAIC, Journal, TREM2, Patent, Investment, Patient, European Patent Office, Arnon Rosenthal, American College, Disease, Maintenance, Contra, EMA, HIV disease progression rates, Manuscript, CSF, FDA, Conference, Total, Safety, GSK, Biomarker, ARIA, PIN, Translational medicine, Amyloid, SAN, Blood, Frontotemporal dementia, Clutch (eggs), Webcast, Microglia, American College of Clinical Pharmacology, Journal of Translational Medicine, Type, MRI, European Patent Convention, Poster, ALEC, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, Food, Pharmaceutical industry, Vaccine, Medical imaging, Research

ET / 1:30 p.m. PT

Key Points: 
  • ET / 1:30 p.m. PT
    SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported second quarter 2023 financial results and recent portfolio and business updates.
  • Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC) in July 2023.
  • In the second quarter of 2023, the U.S. Patent and Trademark Office issued patents covering methods of treatment using AL002.
  • Alector’s management team will host a conference call discussing Alector’s results for the second quarter of 2023 and provide a business update.

NDA Partners Appoints Alexander Vinks, PhD, PharmD, FCP, Prominent Clinical Pharmacologist, as Partner in the Firm

Retrieved on: 
Wednesday, March 22, 2023
Clinical pharmacology, FCP, Doctor of Pharmacy, American College of Clinical Pharmacology, University, College of Medicine, Pharmacometrics, Clinical trial, PPRU, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Cincinnati Children's Hospital Medical Center, NICHD, Doctor of Philosophy, Partner, Division, Drug development, Human development, Pharmacy, Knowledge, Principal, American College, FDA, Pharmacology, Leiden University, Pharmaceutical industry, Nursing

WASHINGTON, March 22, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Alexander (Sander) A. Vinks, PhD, PharmD, FCP, a prominent pediatric and adult clinical pharmacologist and pediatric clinical trials expert, has been appointed as Partner in the firm.

Key Points: 
  • NDA Partners' Vice President and General Manager, Eric Fish, announced today that Alexander (Sander) A. Vinks, PhD, PharmD, FCP, prominent clinical pharmacologist and pediatric clinical trials expert, has been appointed as Partner in the firm.
  • WASHINGTON, March 22, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Alexander (Sander) A. Vinks, PhD, PharmD, FCP , a prominent pediatric and adult clinical pharmacologist and pediatric clinical trials expert, has been appointed as Partner in the firm.
  • Dr. Vinks joins as Partner to lead the firm's Pediatric Drug Development Practice and further expand the clinical pharmacology and clinical trial design services within NDA Partners.
  • He is board certified in clinical pharmacology and is a fellow of the American College of Clinical Pharmacology.

Precision Medicine Group Appoints John Hubbard, PhD, as Board of Directors Chair

Retrieved on: 
Monday, March 13, 2023
PMG, Strategic planning, Science 37, Toxicology and Applied Pharmacology, Doctor of Philosophy, Senior, Translation, Pharmacology, American College of Clinical Pharmacology, Science, Diplomate of National Board, Enterprise, American College, Personalized medicine, Development, Drug development, ChromeOS, ICON, DevOps, ICON PLC, Pfizer, Management, Nursing

BETHESDA, Md., March 13, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.

Key Points: 
  • BETHESDA, Md., March 13, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
  • "We are thrilled to welcome John to our Board.
  • He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development," said Mark Clein, Chief Executive Officer of Precision Medicine Group.
  • Earlier, he was Group President of ICON plc's Global Clinical Research Services Division, one of the top five global CROs.

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

Retrieved on: 
Thursday, November 3, 2022
Company, Journal, Private Securities Litigation Reform Act, American College, Primary biliary cholangitis, Board, The Journal of Clinical Pharmacology, Serica, GLOBE, American College of Clinical Pharmacology, Atopic dermatitis, Chronic kidney disease, FDA, Translational medicine, Medicine, Senior, Itch, CEP, Therapy, Nasdaq, Michigan State University, Form 10-Q, Alkermes, Pharmacology, U.S. Securities and Exchange Commission, David Berry (inventor), Wellesley College, Board of directors, Notalgia paresthetica, Security (finance), Michigan State University College of Human Medicine, Patient, Pharmaceutical industry

STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.

Key Points: 
  • STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.
  • Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc.
    We are very pleased to welcome Lisa to our board of directors, said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics.
  • Its an exciting time to be joining the board of Cara Therapeutics, said Dr. von Moltke.
  • Dr. von Moltke has directed successful development programs, led clinical teams, and interacted with regulatory agencies across multiple therapeutic areas.

ACCP Position Statements: "Regulation of Dietary Supplements and Nutraceutical Products in the United States: An Argument for Greater Oversight and Uniform Standards" & "Front-Line Healthcare Professionals Lack Critical Knowledge in Dietary Supplement and

Retrieved on: 
Tuesday, January 25, 2022
Knowledge, Association, Good manufacturing practice, Patient, Continuing education, Dietary supplement, Publication, RN, American College of Clinical Pharmacology, CME, Population, Accreditation Council, Alternative, ACPE, Public health, Health, GMP, CPE, View, Drug, Accreditation, Accreditation Council for Pharmacy Education, Doctor of Pharmacy, DO, Education, Nutraceutical, MD, ACCP, Multimedia, HCP, American College, Awareness, Medicine

ASHBURN, Va., Jan. 25, 2022 /PRNewswire/ --Two Position Papers from the American College of Clinical Pharmacology (ACCP) have been published on the topic of dietary supplements and nutraceuticals .

Key Points: 
  • ASHBURN, Va., Jan. 25, 2022 /PRNewswire/ --Two Position Papers from the American College of Clinical Pharmacology (ACCP) have been published on the topic of dietary supplements and nutraceuticals .
  • Regulation of Dietary Supplements and Nutraceutical Products in the United States: An Argument for Greater Oversight and Uniform Standards " is a call to action on improving the regulatory framework of dietary supplements and nutraceutical products to ensure healthcare professionals, consumers and patients have access to safe and adequately labeled products.
  • Front-Line Healthcare Professionals Lack Critical Knowledge in Dietary Supplement and Nutraceutical Products: A Call to Action for Comprehensive Educational Opportunities " is a call to action on improving front-line health care professional (HCP) knowledge on complementary and integrative medicine, supplements and herbal products purported to improve health.
  • ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals.

ACCP Policy Statements: "Off-Label Use of Ketamine: A Challenging Drug Treatment Delivery Model with an Inherently Unfavorable Risk-Benefit Profile" & "Pharmacological Arguments Against the Use of Ketamine in Non-Medical Settings"

Retrieved on: 
Tuesday, January 11, 2022
Use, Association, Patient, Continuing education, State, Disclosure, Publication, American College of Clinical Pharmacology, Drug, Traditional Malaysian musical instruments, View, Fatality, Attention, ACCP, Guideline, Multimedia, American College, FDA, Human, Physician, Policy, Awareness, Medical device, Pharmaceutical industry, Ketamine

Ketamine is a dissociative anesthetic agent that is FDA-approved for use by or under the direction of physicians experienced in the administration of general anesthetics.

Key Points: 
  • Ketamine is a dissociative anesthetic agent that is FDA-approved for use by or under the direction of physicians experienced in the administration of general anesthetics.
    "
  • OffLabel Use of Ketamine: A Challenging Drug Treatment Delivery Model with an Inherently Unfavorable RiskBenefit Profile " draws the attention of the public, State-elected officials and the FDA to the administration of ketamine for off-label medical usage.
  • Based on these arguments, ACCP joins other professional and medical organizations in strongly opposing the non-medical use of ketamine for law enforcement purposes in individuals without justifiable medical reasons for its administration.
  • ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals.

2021 Virtual Annual Meeting of the American College of Clinical Pharmacology® - The Premier Clinical Pharmacology Educational & Scientific Meeting

Retrieved on: 
Tuesday, May 4, 2021
Health care, Health sciences, Health, American College of Clinical Pharmacology, ACCP, Medical education in the United States, Medical education, ACPE, American Nurses Credentialing Center, Accreditation Council for Continuing Medical Education, Pharmacy school, Continuing medical education

b'ASHBURN, Va., May 4, 2021 /PRNewswire/ --The American College of Clinical Pharmacology(ACCP) is pleased to announce the 2021 ACCP Virtual Annual Meeting (#2021ACCP) which will be held September 13 17, 2021.

Key Points: 
  • b'ASHBURN, Va., May 4, 2021 /PRNewswire/ --The American College of Clinical Pharmacology(ACCP) is pleased to announce the 2021 ACCP Virtual Annual Meeting (#2021ACCP) which will be held September 13 17, 2021.
  • We encourage you to join us for this outstanding educational and scientific event!
  • ACCP provides healthcare professionals and scientists with a forum to exchange knowledge and ideas that promote and expand the value of clinical pharmacology in healthcare and drug development.\nEarly Bird registration ends June 30, 2021, reserve your seat today .\nNetworking breakout sessions throughout the meeting, including a Virtual Happy Hour\nTwo Pre-meeting Workshops will be hosted September 11th and 12th and are available for a separate fee.\nAvailable on September 10th are a series of events focused on Students, Trainees & Early-stage Professionals , including a virtual Welcome & Coffee Chat, a Panel Discussion on how to thrive in the new hybrid workplace model and a Networking Social.\nACCP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.\nACCP hosts multiple Live Webinars throughout the year and are archived for On Demand viewing.
  • ACCP upcoming webinars are:\n'

Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting

Retrieved on: 
Monday, September 21, 2020
Psychoactive drugs, Opioids, Drugs, Euphoriants, Morphinans, RTT, Opiates, Morphine, American College of Clinical Pharmacology, ACCP, Pharmacology, Clinical pharmacology

CHESTERBROOK, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting, taking place from September 21st to 23rd, 2020.

Key Points: 
  • CHESTERBROOK, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting, taking place from September 21st to 23rd, 2020.
  • Simulations were conducted to determine potential therapeutic doses, which informed a proof-of-concept trial recently initiated by Imperial College London.
  • The clinical utility function model predicted there would be a lower probability of a respiratory event occurring with OLINVYK versus morphine.
  • In previous clinical trials, there was a low dropout rate associated with TRV027, and no significant safety issues were reported.

2020 Annual Meeting of the American College of Clinical Pharmacology® - The Premier Clinical Pharmacology Educational & Scientific Meeting

Retrieved on: 
Tuesday, April 14, 2020
American College of Clinical Pharmacology, Health, ACCP, Articles, Clinical pharmacology, Life sciences, Pharmacology, Bethesda, Maryland

ASHBURN, Va., April 14, 2020 /PRNewswire/ --The American College of Clinical Pharmacology(ACCP) is pleased to announce the 2020 ACCP Annual Meeting (#2020ACCP) which will be held September 20 22, 2020 at the Bethesda N Marriott Hotel & Conference Center in Bethesda, MD.

Key Points: 
  • ASHBURN, Va., April 14, 2020 /PRNewswire/ --The American College of Clinical Pharmacology(ACCP) is pleased to announce the 2020 ACCP Annual Meeting (#2020ACCP) which will be held September 20 22, 2020 at the Bethesda N Marriott Hotel & Conference Center in Bethesda, MD.
  • We strongly encourage you to join us for this outstanding educational and scientific event!
  • ACCP provides healthcare professionals and scientists with a forum to exchange knowledge and ideas that promote and expand the value of clinical pharmacology in healthcare and drug development.
  • Early Bird registration ends June 30, 2020, click here to learn more and register.